logo
logo

Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing To Advance Next-Generation Precision Editing Therapeutics

Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing To Advance Next-Generation Precision Editing Therapeutics

11/09/21, 7:00 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgcambridge
Money raised
$215 million
Round Type
series b
Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the completion of an oversubscribed and up-sized $215 million Series B financing. Including this round, the Company has raised over $300 million to date.

Company Info

Company
Arbor
Location
cambridge, maryland, united states
Additional Info
We welcome Dr. Yu to the board and look forward to his contributions as the company works toward deploying these new therapies to treat patients in the near future.”